Market Closed -
Other stock markets
|
Pre-market 08:11:28 | |||
803.2 USD | +2.55% | 807.5 | +0.54% |
06:42am | Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment | MT |
06:27am | China Grants Green Light to Eli Lilly's Diabetes Treatment | MT |
Sales 2024 * | 43B 58.72B | Sales 2025 * | 52.61B 71.86B | Capitalization | 723B 988B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B 16.3B | Net income 2025 * | 16.55B 22.61B | EV / Sales 2024 * | 17.3 x |
Net Debt 2024 * | 19.98B 27.29B | Net Debt 2025 * | 15.29B 20.88B | EV / Sales 2025 * | 14 x |
P/E ratio 2024 * |
60.1
x | P/E ratio 2025 * |
43.2
x | Employees | 43,000 |
Yield 2024 * |
0.65% | Yield 2025 * |
0.75% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | +0.28% | ||
1 week | +5.13% | ||
Current month | +2.83% | ||
1 month | +10.58% | ||
3 months | +7.68% | ||
6 months | +35.53% | ||
Current year | +37.78% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.49% | 17 M€ | +8.99% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 803.2 | +2.55% | 4,334,499 |
24-05-20 | 783.2 | +1.71% | 2,188,818 |
24-05-17 | 770 | -0.15% | 1,670,317 |
24-05-16 | 771.1 | -2.02% | 2,299,653 |
24-05-15 | 787 | +3.02% | 3,038,253 |
Delayed Quote Nyse, May 21, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.78% | 723B | |
+31.11% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.25% | 244B | |
-4.79% | 208B | |
+9.97% | 210B | |
+9.32% | 169B | |
-0.80% | 162B |
- Stock Market
- Equities
- LLY Stock